Home » Stocks » ADCT

ADC Therapeutics SA (ADCT)

Stock Price: $21.89 USD -1.40 (-6.01%)
Updated Apr 19, 2021 2:56 PM EDT - Market open
Market Cap 1.79B
Revenue (ttm) n/a
Net Income (ttm) -246.29M
Shares Out 76.72M
EPS (ttm) -3.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $21.89
Previous Close $23.29
Change ($) -1.40
Change (%) -6.01%
Day's Open 23.19
Day's Range 21.89 - 23.55
Day's Volume 168,582
52-Week Range 21.51 - 56.59

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON, SHANGHAI & LAUSANNE, Switzerland--(BUSINESS WIRE)--Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals and ADC Therapeutics SA (NYSE: ADCT), today announced the appointm...

1 week ago - Business Wire

One trading strategy an investor can profitably employ is to pick up an undervalued asset that has sold off due to factors that are extraneous or intrinsic to it. The strategy is premised on the belief ...

Other stocks mentioned: BIGC, GNENF
2 weeks ago - Benzinga

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of potent and targ...

1 month ago - Business Wire

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent a...

1 month ago - Business Wire

ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent an...

1 month ago - Business Wire

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent an...

2 months ago - Business Wire

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent an...

2 months ago - Business Wire

ADC Therapeutics SA (ADCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago - Zacks Investment Research

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent an...

3 months ago - Business Wire

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent an...

3 months ago - Business Wire

Overland Pharmaceuticals will form a $117 million China JV with Allogene Therapeutics to bring allogenic CAR-T drugs to China. Harbour BioMed has out-licensed its fully human SARS-CoV-2 neutralizing ant...

Other stocks mentioned: ABBV, ALLO, BNTX, LEGN, YMAB
3 months ago - Seeking Alpha

LAUSANNE, Switzerland & SHANGHAI & BOSTON--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT) and Overland Pharmaceuticals, a fully integrated biopharmaceutical company backed by Hillhouse Capital, today ...

4 months ago - Business Wire

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent an...

4 months ago - Business Wire

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent an...

4 months ago - Business Wire

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent a...

4 months ago - Business Wire

ADC Therapeutics' (ADCT) CEO Chris Martin on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent a...

5 months ago - Business Wire

ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

5 months ago - Zacks Investment Research

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent a...

5 months ago - Business Wire

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent a...

5 months ago - Business Wire

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent an...

5 months ago - Business Wire

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent a...

5 months ago - Business Wire

Media Release Copenhagen, Denmark and Lausanne, Switzerland, October 30, 2020

Other stocks mentioned: GMAB
5 months ago - GlobeNewsWire

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent a...

6 months ago - Business Wire

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent an...

6 months ago - Business Wire

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent an...

6 months ago - Business Wire

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent a...

6 months ago - Business Wire

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent a...

7 months ago - Business Wire

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent a...

7 months ago - Business Wire

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), today gave notice that Morgan Stanley & Co. LLC and BofA Securities, Inc.

7 months ago - Business Wire

ADC Therapeutics SA (ADCT) CEO Christopher Martin on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent a...

8 months ago - Business Wire

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent a...

8 months ago - Business Wire

AMSTERDAM--(BUSINESS WIRE)--Synaffix B.V., a biotechnology company focused on enabling antibody-drug conjugates (ADCs) with superior therapeutic index based on its proprietary ADC technology platform, a...

8 months ago - Business Wire

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent an...

9 months ago - Business Wire

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a clinical-stage oncology-focused biotechnology company leading the development and commercialization of next-generation antibody...

9 months ago - Business Wire

VIRGINIA BEACH, Va., June 30, 2020 /PRNewswire/ -- New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of its portfo...

9 months ago - PRNewsWire

ADC Therapeutics S.A. ADCT, +59.10% shares rocketed 56% Friday in their trading debut, after the Swiss biotech's initial public offering priced above its proposed price range and underwriters increased ...

11 months ago - Market Watch

About ADCT

ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in com... [Read more...]

Industry
Biotechnology
IPO Date
May 15, 2020
Stock Exchange
NYSE
Ticker Symbol
ADCT
Full Company Profile

Financial Performance

Financial Statements